Goal-Directed Fluid Therapy Enhances Gastrointestinal Recovery after Laparoscopic Surgery: A Systematic Review and Meta-Analysis.
Marcell VirágMáté RottlerNoémi GedeKlementina OcskayTamas LeinerMáté TubaSzabolcs ÁbrahámNelli FarkasPéter HegyiZsolt MolnárPublished in: Journal of personalized medicine (2022)
(1) Background: Whether goal-directed fluid therapy (GDFT) provides any outcome benefit as compared to non-goal-directed fluid therapy (N-GDFT) in elective abdominal laparoscopic surgery has not been determined yet. (2) Methods: A systematic literature search was conducted in MEDLINE, Embase, CENTRAL, Web of Science, and Scopus. The main outcomes were length of hospital stay (LOHS), time to first flatus and stool, intraoperative fluid and vasopressor requirements, serum lactate levels, and urinary output. Pooled risks ratios (RRs) with 95% confidence intervals (CI) were calculated for dichotomous outcomes and weighted mean difference (WMD) with 95% CI for continuous outcomes. (3) Results: Eleven studies were included in the quantitative, and fifteen in the qualitative synthesis. LOHS (WMD: -1.18 days, 95% CI: -1.84 to -0.53) and time to first stool (WMD: -9.8 h; CI -12.7 to -7.0) were significantly shorter in the GDFT group. GDFT resulted in significantly less intraoperative fluid administration (WMD: -441 mL, 95% CI: -790 to -92) and lower lactate levels at the end of the operation: WMD: -0.25 mmol L -1 ; 95% CI: -0.36 to -0.14. (4) Conclusions: GDFT resulted in enhanced recovery of the gastrointestinal function and shorter LOHS as compared to N-GDFT.
Keyphrases
- laparoscopic surgery
- patients undergoing
- systematic review
- magnetic resonance
- public health
- stem cells
- clinical trial
- randomized controlled trial
- emergency department
- magnetic resonance imaging
- type diabetes
- risk assessment
- metabolic syndrome
- bone marrow
- adipose tissue
- mesenchymal stem cells
- high resolution
- insulin resistance
- case control
- acute care
- human health